Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT03501680

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT03501680
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03501680. Randomized; no masking; primary purpose treatment. Start 2018-06-06 (anticipated); primary completion 2020-03-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Intensive Insulin for Severe/Moderate Hypertriglyceridemia Pancreatitis.
Acronym
HAPinsulin
Condition
Acute Pancreatitis
Condition
Hypertriglyceridemia
Intervention (Drug)
Insulin
Intervention (Device)
plasmapheresis
Lead sponsor
First Affiliated Hospital of Wenzhou Medical University (class: other)

Record details

Record id
cardio:ct-nct03501680
Content hash
7739220fbcdec8fcf813b89d42c5ff4d7c57c861d670007c199f0cf81d87aef8